Top

Published in:

01-04-2018 | IM - COMMENTARY

Pancreatic cancer: risk and preventive factors

Authors: Anna Licata, Giuseppe Montalto, Maurizio Soresi

Published in: Internal and Emergency Medicine | Issue 3/2018

Excerpt

In Asian countries, the increasing incidence of obesity has only recently opened a debate that has been ongoing in the West for a long time, not only regarding its cardiovascular consequences, but also the relationship between obesity, non-alcoholic fatty liver disease (NAFLD), and cancer [1, 2]. …

Koh JC, Loo WM, Goh KL et al (2016) Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol 31(8):1405–1413. https://doi.org/10.1111/jgh.13385 CrossRefPubMed

Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A (2016) Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 11(1):3–10CrossRefPubMed

Chang CF, Tseng YC, Huang HH, Shih YL, Hsieh TY, Lin HH (2017) Exploring the relationship between non-alcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. Intern Emerg Med. https://doi.org/10.1007/s11739-017-1774-x

Włodarek D, Jerzy Podleśny JS (2007) Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Roczniki Państwowego Zakładu 58(1):129

Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, Polesel J et al (2011) Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 60:1372–1378. https://doi.org/10.1016/j.metabol.2011.03.005 CrossRefPubMed

Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Metabolic Syndrome Study Group et al (2013) Non-alcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol 50(2):241–249. https://doi.org/10.1007/s00592-012-0406-1 CrossRefPubMed

Smits MM, van Geenen EJ (2011) The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 8(3):169–177. https://doi.org/10.1038/nrgastro.2011.4 CrossRefPubMed

Pacifico L, Di Martino M, Anania C, Andreoli GM, Bezzi M, Catalano C et al (2015) Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J Gastroenterol 21(15):4688–4695. https://doi.org/10.3748/wjg.v21.i15.4688 CrossRefPubMedPubMedCentral

Després JP (2006) Lemieux I abdominal obesity and metabolic syndrome. Nature 444:881–887CrossRefPubMed

10.

Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E et al (2015) Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf) 83(5):656–662. https://doi.org/10.1111/cen.12862 CrossRef

11.

Soresi M, Giannitrapani L, Florena AM, La Spada E, Di Gesaro V, Rappa F et al (2009) Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 64:1181–1187CrossRefPubMed

12.

Gullo L, Salizzoni E, Serra C, Calculli L, Bastagli L, Migliori M (2006) Can pancreatic steatosis explain the finding of pancreatic hyperenzymemia in subjects with dyslipidemia? Pancreas 33(4):351–353CrossRefPubMed

13.

Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC et al (2010) Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer 126(10):2394–2403. https://doi.org/10.1002/ijc.24907 PubMed

14.

Cui X, Xie Y, Chen M, Li J, Liao X, Shen J et al (2012) Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23(7):1099–1111. https://doi.org/10.1007/s10552-012-9979-9 CrossRefPubMed

15.

Khurana V, Sheth A, Caldito G, Barkin JS (2007) Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34:260–265CrossRefPubMed

16.

Walker EJ, Ko AH, Holly EA, Bracci PM (2015) Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 121:1287–1294CrossRefPubMedPubMedCentral

17.

Archibugi L, Piciucchi M, Stigliano S, Valente R, Zerboni G, Barucca V et al (2017) Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study. Sci Rep 7(1):13024. https://doi.org/10.1038/s41598-017-13430-z CrossRefPubMedPubMedCentral

18.

Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L (2016) Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 1866(2):163–176. https://doi.org/10.1016/j.bbcan.2016.08.002 PubMed

19.

Zhang YP, Wan YD, Sun YL, Li J, Zhu RT (2015) Aspirin might reduce the incidence of pancreatic cancer: a meta-analysis of observational studies. Sci Rep 5:15460. https://doi.org/10.1038/srep15460 CrossRefPubMedPubMedCentral

20.

Polimeni L, Pastori D, Baratta F, Tozzi G, Novo M, Vicinanza R et al (2017) Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Intern Emerg Med 12(8):1159–1165CrossRefPubMed

Title: Pancreatic cancer: risk and preventive factors
Authors: Anna Licata
Giuseppe Montalto
Maurizio Soresi
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: Internal and Emergency Medicine / Issue 3/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-018-1795-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Effect of emergency physician burnout on patient waiting times

Mild troponin elevation in patients admitted to the emergency department with atrial fibrillation: 30-day post-discharge prognostic significance

Posterior reversible encephalopathy with brainstem involvement

ERCP or NO ERCP: the case report of a frail patient

Sarcoidosis: a review for the internist

Toxic alcohol diagnosis and management: an emergency medicine review

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage